Finally, we described that treatment of SARS-CoV-2 infected RMs with baricitinib, a JAK1/2 inhibitor recently demonstrated to reduce hospitalization time and mortality for severe COVID-19 patients25, suppressed airway inflammation by abrogating the infiltration of pro-inflammatory macrophages to the alveolar space. The gene discussed is JAK1; the disease is COVID-19.